



PRESS RELEASE

AVIOR TO PRESENT AND PARTICIPATE AT THE 23rd H.C. WAINWRIGHT ANNUAL GLOBAL INVESTMENT CONFERENCE

CARY, N.C., Sept. 7, 2021 -- Avior Bio Inc. is a clinical-stage, pharmaceutical company advancing therapies in pruritus and various forms of inflammatory skin conditions today announced that Dr Niraj Vasisht, President and Chief Executive Officer and Dr Andrew Finn, Chief Medical Officer will present and participate in one-on-one investor meetings at the 23rd H.C. Wainwright Annual Global Investment Conference taking place on September 13-15, 2021.

The fireside chat at the 23rd H.C. Wainwright Annual Global Investment Conference will be available to conference registrants on-demand beginning Monday, September 13, 2021, at 7:00 AM ET. Institutional investors interested in a one-on-one meeting should contact their H.C. Wainwright institutional representative.

About Avior:

We are a rapidly growing pharmaceutical company dedicated to the treatment of pruritus and inflammatory skin disorders manifested from liver and kidney disease. Our lead molecule - AV104 - has demonstrated efficacy in treating pruritus (itch) in rare disease - primary biliary cholangitis (PBC) - with the potential to expand into other chronic liver disease-associated pruritus conditions. AV104 is a buccal film where the route administration bypasses the impaired liver for effective drug distribution. Our management team has a track record of clinical and regulatory success in bringing several products to market. For further information about Avior Bio Incorporated, visit their website at www.AviorBio.com.

The Unmet Need:

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis (PSC) are rare liver diseases where patients suffer from intractable itching. There are approximately 105,000 patients in PBC and 62,000 in PSC that suffer from moderate-to-severe chronic pruritus. In this disease state, unfortunately, there are no FDA-approved therapies available for the treatment of pruritus. With about 2.5 million patients suffering liver disease-associated pruritus, AV104 represents a significant commercial product opportunity.